This company listing is no longer active
Covetrus (CVET) Stock Overview
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CVET Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Covetrus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.99 |
| 52 Week High | US$21.20 |
| 52 Week Low | US$13.39 |
| Beta | 1.51 |
| 1 Month Change | 0.53% |
| 3 Month Change | 0.91% |
| 1 Year Change | 5.58% |
| 3 Year Change | 107.00% |
| 5 Year Change | n/a |
| Change since IPO | -50.02% |
Recent News & Updates
Recent updates
Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line
Aug 04Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders
Jun 02Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price
May 02
Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?
Jan 07We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Oct 21An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued
Sep 16Estimating The Intrinsic Value Of Covetrus, Inc. (NASDAQ:CVET)
May 31Is Covetrus (NASDAQ:CVET) Using Too Much Debt?
May 05Who Has Been Selling Covetrus, Inc. (NASDAQ:CVET) Shares?
Feb 26We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Jan 22Covetrus (NASDAQ:CVET) Shareholders Have Enjoyed An Impressive 106% Share Price Gain
Dec 18
Shareholder Returns
| CVET | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.1% | 1.9% |
| 1Y | 5.6% | -14.5% | 17.8% |
Return vs Industry: CVET matched the US Healthcare industry which returned 4.9% over the past year.
Return vs Market: CVET exceeded the US Market which returned -25.8% over the past year.
Price Volatility
| CVET volatility | |
|---|---|
| CVET Average Weekly Movement | 0.3% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CVET has not had significant price volatility in the past 3 months.
Volatility Over Time: CVET's weekly volatility has decreased from 6% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 4,873 | Ben Wolin | www.covetrus.com |
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners.
Covetrus, Inc. Fundamentals Summary
| CVET fundamental statistics | |
|---|---|
| Market cap | US$2.94b |
| Earnings (TTM) | -US$13.00m |
| Revenue (TTM) | US$4.65b |
Is CVET overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVET income statement (TTM) | |
|---|---|
| Revenue | US$4.65b |
| Cost of Revenue | US$3.77b |
| Gross Profit | US$882.00m |
| Other Expenses | US$895.00m |
| Earnings | -US$13.00m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.093 |
| Gross Margin | 18.97% |
| Net Profit Margin | -0.28% |
| Debt/Equity Ratio | 68.7% |
How did CVET perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/16 09:21 |
| End of Day Share Price | 2022/10/12 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Covetrus, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Robert Eich | Cleveland Research Company |
| Nathan Rich | Goldman Sachs |